All In MedTech

FDA Clearance Tracker · P150045

ZEUS ELISA PARVOVIRUS B19 IGG TEST SYSTEM

Premarket approval (PMA) is the pathway for the highest-risk devices. FDA reviews clinical evidence of safety and effectiveness before approving.

Last checked: Nov 19, 2026Latest source record: Sep 19, 2017 (this decision)Source: openFDAMethods & limitations

PMA

Decided

Sep 19, 2017

Approved

Time to decision

665 days

Received Nov 24, 2015. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA

Device class

Class III

The decision

FDA number
P150045
Device name
ZEUS ELISA PARVOVIRUS B19 IGG TEST SYSTEM
Applicant location
Branchburg, NJ
Received
Nov 24, 2015
Decided
Sep 19, 2017
Decision
Approved

Device type

Device class
Class III

Every decision under product code MYL

FDA's approval statement

As written in FDA's record.

Approval for the ZEUS ELISA Parvovirus B19 IgG Test System is intended for the qualitative detection of IgG class antibodies to human parvovirus B19 in human serum including women of childbearing age where there is a suspicion of exposure to human parvovirus B19. The test is also for all symptomatic patients as an aid in the diagnosis of fifth disease (erythema infectiosum). This test is for in vitro diagnostic use only.

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • It is not the first decision under product code MYL. The earliest in FDA's data is P970054, decided Aug 6, 1999.
  • It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.

Source documents

Other decisions for Zeus Scientific, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

2 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.